Clinical trial NCT00199940: Safety And Efficacy Study Of Ziprasidone In Pediatric Psychotic Illness
Official title: A Pilot Open Trial Of Ziprasidone, Early In The Course Of Pediatric Psychotic Illness
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Schizophrenia
Affective Disorders
Psychotic Disorder
Psychotic Mood Disorder
Keywords: Schizophrenia
Pediatric psychotic disorders
Ziprasidone
Lead sponsor: Medical College of Wisconsin
Sponsor class: OTHER
First posted: 2005-09-20
Enrollment: 20
Sex: ALL
Minimum age (years): 7
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this research is to determine if Ziprasidone is safe and effective for use in children and adolescents with a psychotic illness, and to determine of Ziprasidone treatment leads to weight changes in children.

Detailed description: Ziprasidone is a recently FDA approved antipsychotic, and it holds promise in the treatment of pediatric psychosis due to its low liability for weight gain and other side effects. This is important because early intervention in persons with a psychotic illness is important for their long-term treatment and outcome. Unfortunately, pediatric samples are often more sensitive to the side effects of psychotropic medications. Because psychotropic medications are often used by clinicians long before they are studied in pediatric populations, it is important to further study these agents.

Twenty subjects with the diagnosis of a psychotic disorder, according to DSM-IV criteria, will be recruited for the study. If subjects have completed baseline evaluations, labs, EKG, and rating scales and are still eligible to participate, subjects will start on 20mg of Ziprasidone at night. The second week this will increase to 20 mg twice a day. At visits that occur at 2,4,6,and 8 weeks, the subject's dose of medication can be increased in 20mg per day increments. This allows for a maximum possible dose of 100mg. Dosage may be decreased at any time secondary to side effects.

The potential benefits are that new information will be added to the field of pediatric psychiatry and the possibility that the medication may result in improved symptoms of psychosis. The potential benefits of this study outweigh the possible risks.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of Schizophrenia, Schizophreniform DO, Schizoaffective DO or Psychotic Disorder NOS
* Male/female, ages 7.0-17 years old
* Normal intelligence, ability to provide assent and consent
* Not currently receiving adequate treatment

Exclusion Criteria:

* Known hypersensitivity to ziprasidone (past failed trial)
* History of QTc prolongation
* Recent myocardial infarction
* Uncompensated heart failure
* Currently treated with other QTc prolonging medications
* Unstable medical illness
* If on diuretics, monitor regularly for hypokalemia

Primary outcomes:
measure: Positive and Negative Symptom Scale (PANSS), score symptoms from baseline through end of study Week 8.
Secondary outcomes:
measure: Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS), assess at baseline only.
measure: Child Depression Rating Scale (CDRS), rate from baseline to Week 8.
measure: Simpson-Angus Rating Scale (SARS), rate from baseline to Week 8.
measure: Abnormal Involuntary Movement Scale (AIMS), rate at baseline, Weeks 2,4,6,8.
measure: Barnes Akathesia Scale (BAS), rate from baseline through Week 8.
measure: Side-Effect For Children & Adolescents (SEFCA), rate from baseline through Week 8.
Other outcomes:
Locations:
Study officials:
affiliation: Medical College of Wisconsin; Children's Hospital of Wisconsin
name: Russell E Scheffer, MD
role: PRINCIPAL_INVESTIGATOR
References: